First, we demonstrated the accumulation of ACh in osimertinib-regressed PDX tumors, but we were not able to validate these phenotypes in clinically fresh specimens because osimertinib-regressed tumors from NSCLC patients upon EGFR-TKI therapy are not readily accessible. This evidence concerns the gene EGFR and non-small cell lung carcinoma.